medwireNews: Tofacitinib could soon be available in Europe for people with ankylosing spondylitis following a recommendation from the EMA to adopt a new indication for the drug.
According to the Committee for Medicinal Products for Human Use, the Janus kinase inhibitor is indicated for adult patients with active disease and an inadequate response to conventional treatment options.
Advertisement
This adds to the previous positive decisions for tofacitinib for the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group